Seagen Stock Price

-3.84 (-2.6%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-3.84 -2.6% 143.65 17:13:12
Open Price Low Price High Price Close Price Prev Close
147.14 143.00 147.14 143.65 147.49
Bid Price Ask Price Spread News
143.00 147.00 4.00 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,266 826,195 $ 145.20 $ 119,967,414 973,136 134.51 - 213.94
Last Trade Time Type Quantity Stock Price Currency
18:16:53 2 $ 147.00 USD

Seagen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 25.71B 179.00M 60.40M $ 916.71M $ 260.07M -0.95 71.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Seagen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week145.19151.905143.00146.60902,675-1.54-1.06%
1 Month140.90151.905134.51142.61935,2512.751.95%
3 Months163.39199.00134.51154.481,167,217-19.74-12.08%
6 Months198.42202.92134.51166.241,059,225-54.77-27.6%
1 Year139.96213.94134.51165.911,073,7373.692.64%
3 Years49.89213.9447.75112.031,006,35693.76187.93%
5 Years39.23213.9432.39590.27981,648104.42266.17%

Seagen Description

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.